

Title (en)
METHODS OF USING LANREOTIDE, A SOMATOSTATIN ANALOGUE

Title (de)
ANWENDUNGSVERFAHREN FÜR LANREOTID, EIN SOMATOSTATIN ANALOGON

Title (fr)
PROCEDES D'UTILISATION D'UN ANALOGUE DE SOMATOSTATINE

Publication
EP 1100532 A2 20010523 (EN)

Application
EP 99937658 A 19990729

Priority
• US 9917294 W 19990729
• US 12652598 A 19980730
• US 9469398 P 19980730

Abstract (en)
[origin: WO0006185A2] The present invention is directed to a method of treating one or more of the following disease and/or conditions, which comprises administering to a patient in need thereof the compound H-g(b)-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂, where the Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, endocrinological diseases and/or conditions, various types of cancers and conditions associated with cancer such as cancer cachexia and in the treatment of hypotension and panic attacks.

IPC 1-7
A61K 38/31; **A61P 1/04**; **A61P 1/12**; **A61P 1/14**; **A61P 1/18**; **A61P 3/08**; **A61P 5/02**; **A61P 5/08**; **A61P 5/18**; **A61P 5/48**; **A61P 9/02**; **A61P 9/10**; **A61P 9/12**; **A61P 17/02**; **A61P 17/06**; **A61P 19/08**; **A61P 25/18**; **A61P 35/00**; **A61P 43/00**

IPC 8 full level
A61K 38/31 (2006.01); **A61P 1/00** (2006.01); **A61P 3/00** (2006.01); **A61P 3/10** (2006.01); **A61P 3/14** (2006.01); **A61P 5/18** (2006.01); **A61P 9/00** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 25/22** (2006.01); **A61P 25/28** (2006.01); **A61P 35/00** (2006.01); **C07K 14/655** (2006.01); **A61K 38/22** (2006.01)

CPC (source: EP KR)
A61K 38/08 (2013.01 - KR); **A61K 38/31** (2013.01 - EP); **A61P 1/00** (2018.01 - EP); **A61P 1/04** (2018.01 - EP); **A61P 1/12** (2018.01 - EP); **A61P 1/14** (2018.01 - EP); **A61P 1/18** (2018.01 - EP); **A61P 3/00** (2018.01 - EP); **A61P 3/08** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 3/14** (2018.01 - EP); **A61P 5/02** (2018.01 - EP); **A61P 5/08** (2018.01 - EP); **A61P 5/18** (2018.01 - EP); **A61P 5/48** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/02** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/12** (2018.01 - EP); **A61P 17/00** (2018.01 - EP); **A61P 17/02** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 19/08** (2018.01 - EP); **A61P 25/18** (2018.01 - EP); **A61P 25/22** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0006185 A2 20000210; **WO 0006185 A3 20000803**; AR 023633 A1 20020904; AU 2004201783 A1 20040527; AU 5244799 A 20000221; AU 770193 B2 20040212; BR 9912609 A 20010502; CA 2335654 A1 20000210; CN 1334742 A 20020206; CZ 2001157 A3 20020213; EP 1100532 A2 20010523; HU P0102839 A2 20020128; HU P0102839 A3 20020228; IL 140837 A0 20020210; IL 181349 A0 20070704; JP 2002521456 A 20020716; KR 20010071071 A 20010728; MX PA01000969 A 20030407; NO 20010481 D0 20010129; NO 20010481 L 20010321; NO 324123 B1 20070827; NZ 509348 A 20040227; PL 346361 A1 20020211

DOCDB simple family (application)
US 9917294 W 19990729; AR P990103765 A 19990729; AU 2004201783 A 20040429; AU 5244799 A 19990729; BR 9912609 A 19990729; CA 2335654 A 19990729; CN 99808953 A 19990729; CZ 2001157 A 19990729; EP 99937658 A 19990729; HU P0102839 A 19990729; IL 14083799 A 19990729; IL 18134907 A 20070215; JP 2000562039 A 19990729; KR 20017001277 A 20010130; MX PA01000969 A 19990729; NO 20010481 A 20010129; NZ 50934899 A 19990729; PL 34636199 A 19990729